Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 28, 2013 03:30 ET | Source: Active Biotech

Antal aktier och röster i Active Biotech

Antalet aktier och röster i Active Biotech har förändrats genom den riktade nyemissionen till Investor som tidigare offentliggjorts. Idag, den sista handelsdagen i månaden, finns totalt 74.923.582...
March 28, 2013 03:30 ET | Source: Active Biotech

Number of shares and votes in Active Biotech

The number of shares and votes in Active Biotech has changed as a result of the directed new issue to Investor as previously announced. Today, the last trading day of the month, there are in...
March 21, 2013 08:00 ET | Source: Active Biotech

EARLY VERSUS DELAYED TREATMENT WITH LAQUINIMOD DEMONSTRATED SIGNIFICANT REDUCTION IN RISK OF DISABILITY PROGRESSION - RESULTS OF THREE-YEAR ALLEGRO STUDY IN RELAPSING-REMITTING MULTIPLE SCLEROSIS

· Data presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) showed early treatment with laquinimod demonstrated significant benefit in terms of slowing disability...
March 21, 2013 08:00 ET | Source: Active Biotech

TIDIG BEHANDLINGSSTART MED LAQUINIMOD VISAR SIGNIFIKANT MINDRE RISK FÖR FUNKTIONSNEDSÄTTNING - TREÅRSRESULTAT FRÅN ALLEGRO, EN KLINISK STUDIE I RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS- PATIENTER

· Data presenterade på "the 65th Annual Meeting of the American Academy of Neurology" (AAN) visar att det är en avsevärd fördel att påbörja behandlingen med laquinimod tidigt för att bromsa...
March 06, 2013 08:00 ET | Source: Active Biotech

FIRST PATIENT ENROLLED IN THIRD PHASE III STUDY OF ORAL LAQUINIMOD FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS

CONCERTO Study Enrolling Patients Globally to Evaluate Impact of Laquinimod on Disability Progression Jerusalem, Israel and Lund, Sweden, March 6, 2013 - Teva Pharmaceutical Industries Ltd. (NYSE:...
March 06, 2013 08:00 ET | Source: Active Biotech

FÖRSTA PATIENTEN REKRYTERAD TILL DEN TREDJE FAS III-STUDIEN AV ORAL LAQUINIMOD FÖR BEHANDLING AV RELAPSERANDE REMITTERANDE MULTIPEL SKLEROS

CONCERTO-studien rekryterar patienter globalt för att utvärdera laquinimods påverkan på funktionsnedsättning Lund, Sverige och Jerusalem, Israel, den 6 mars, 2013 - Active Biotech (NASDAQ OMX...
March 06, 2013 02:30 ET | Source: Active Biotech

Active Biotech tillförs 270 miljoner kronor genom en riktad nyemission till Investor

Lund den 6 mars 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) offentliggör idag att bolagets styrelse, med stöd av årsstämmans bemyndigande 2012, har beslutat att emittera totalt 6 000 000 nya...
March 06, 2013 02:30 ET | Source: Active Biotech

Active Biotech raises SEK 270 million through a directed new issue to Investor

Lund, Sweden, March 6, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) today announces that the company's Board of Directors has, based on the 2012 annual general meeting's authorization, resolved...
February 14, 2013 02:30 ET | Source: Active Biotech

Active Biotech AB Year-end report January - December 2012

Events for the full year 2012Laquinimod Phase III data presented at the AAN (64th Annual Meeting of the American Academy of Neurology)Application submitted for regulatory approval in the EU,...
February 14, 2013 02:30 ET | Source: Active Biotech

Active Biotech AB Bokslutsrapport januari - december 2012

Händelser under helåret 2012Laquinimod fas III-data presenterade på AAN (64th Annual Meeting of the American Academy of Neurology) registreringsansökan inlämnad i EU, 5 MUSD i...